The Experts below are selected from a list of 7002 Experts worldwide ranked by ideXlab platform
Simon Francis Thomsen - One of the best experts on this subject based on the ideXlab platform.
-
autoinflammatory syndromes associated with Hidradenitis Suppurativa and or acne
International Journal of Dermatology, 2017Co-Authors: Caroline Vinkel, Simon Francis ThomsenAbstract:Autoinflammatory syndromes associated with Hidradenitis Suppurativa (HS) and/or acne are rare but potentially debilitating disorders if not diagnosed and treated correctly. They share a common pathogenesis involving a dysregulated innate immune system with abnormal interleukin (IL)-1 signaling leading to sterile neutrophilic inflammation. The clinical features are recurrent episodes of fever, painful arthritis, and skin lesions consistent with HS, acne, and pyoderma gangrenosum (PG) accompanied by elevated systemic inflammatory markers in blood. So far, several clinically different syndromes have been reported in the literature including pyoderma gangrenosum, acne, and pyogenic arthritis (PAPA), pyoderma gangrenosum, acne, and Hidradenitis Suppurativa (PASH), pyoderma gangrenosum, acne, and spondyloarthritis (PASS), pyoderma gangrenosum, acne, pyogenic arthritis, and Hidradenitis Suppurativa (PAPASH), psoriatic arthritis, pyoderma gangrenosum, acne, and Hidradenitis Suppurativa (PsAPASH), and pyoderma gangrenosum, acne, and ulcerative colitis (PAC). The rarity of the syndromes complicates the establishment of evidence-based treatment guidelines. Furthermore, treatment can be challenging due to lack of response to standard treatment modalities. Therefore, it is important to increase the awareness about these diseases in order to optimize disease management and ultimately improve the quality of life of patients.
-
The role of interleukin-17 in the pathogenesis of Hidradenitis Suppurativa.
Dermatology online journal, 2017Co-Authors: Yiqiu Yao, Simon Francis ThomsenAbstract:Hidradenitis Suppurativa is a chronic inflammatory skin condition affecting primarily the axillary, perianal, and inguinal areas. Patients with Hidradenitis Suppurativa present with occlusion and subsequent rupture of follicular ducts, profound abscesses, fistulae, odorous discharge, fibrosis, and scar formation, causing significant morbidity. Knowledge of the pathogenesis of Hidradenitis Suppurativa is limited and treatment with antimicrobial drugs, immunosuppressants, and surgical procedures have shown varying results. The pathogenic role of the interleukin-17 cytokine family in chronic inflammatory skin conditions has been described. Interleukin-17A and interleukin-17F have similar properties and induce the production of cytokines, chemokines, antimicrobial peptides, and metalloproteinases, all of which take part in the inflammatory response. The efficacy of anti-interleukin-17A therapy in psoriasis has also been proven and anti- interleukin-17A drugs are already in use for this condition. There is currently no consensus on the role of interleukin-17 in the pathogenesis of Hidradenitis Suppurativa. Studies have demonstrated increased interleukin-17 mRNA expression in lesional Hidradenitis Suppurativa skin, whereas the protein concentrations of interleukin-17 were found to be normal compared to healthy control skin in one other study. A phase II clinical trial on anti- interleukin-17 therapy in Hidradenitis Suppurativa is ongoing.
-
Autoinflammatory syndromes associated with Hidradenitis Suppurativa and/or acne.
International Journal of Dermatology, 2017Co-Authors: Caroline Vinkel, Simon Francis ThomsenAbstract:Autoinflammatory syndromes associated with Hidradenitis Suppurativa (HS) and/or acne are rare but potentially debilitating disorders if not diagnosed and treated correctly. They share a common pathogenesis involving a dysregulated innate immune system with abnormal interleukin (IL)-1 signaling leading to sterile neutrophilic inflammation. The clinical features are recurrent episodes of fever, painful arthritis, and skin lesions consistent with HS, acne, and pyoderma gangrenosum (PG) accompanied by elevated systemic inflammatory markers in blood. So far, several clinically different syndromes have been reported in the literature including pyoderma gangrenosum, acne, and pyogenic arthritis (PAPA), pyoderma gangrenosum, acne, and Hidradenitis Suppurativa (PASH), pyoderma gangrenosum, acne, and spondyloarthritis (PASS), pyoderma gangrenosum, acne, pyogenic arthritis, and Hidradenitis Suppurativa (PAPASH), psoriatic arthritis, pyoderma gangrenosum, acne, and Hidradenitis Suppurativa (PsAPASH), and pyoderma gangrenosum, acne, and ulcerative colitis (PAC). The rarity of the syndromes complicates the establishment of evidence-based treatment guidelines. Furthermore, treatment can be challenging due to lack of response to standard treatment modalities. Therefore, it is important to increase the awareness about these diseases in order to optimize disease management and ultimately improve the quality of life of patients.
-
The role of interleukin-17 in the pathogenesis of Hidradenitis Suppurativa - eScholarship
Dermatology Online Journal, 2017Co-Authors: Yiqiu Yao, Simon Francis ThomsenAbstract:Hidradenitis Suppurativa is a chronic inflammatory skin condition affecting primarily the axillary, perianal, and inguinal areas. Patients with Hidradenitis Suppurativa present with occlusion and subsequent rupture of follicular ducts, profound abscesses, fistulae, odorous discharge, fibrosis, and scar formation, causing significant morbidity. Knowledge of the pathogenesis of Hidradenitis Suppurativa is limited and treatment with antimicrobial drugs, immunosuppressants, and surgical procedures have shown varying results. The pathogenic role of the interleukin-17 cytokine family in chronic inflammatory skin conditions has been described. Interleukin-17A and interleukin-17F have similar properties and induce the production of cytokines, chemokines, antimicrobial peptides, and metalloproteinases, all of which take part in the inflammatory response. The efficacy of anti-interleukin-17A therapy in psoriasis has also been proven and anti- interleukin-17A drugs are already in use for this condition. There is currently no consensus on the role of interleukin-17 in the pathogenesis of Hidradenitis Suppurativa. Studies have demonstrated increased interleukin-17 mRNA expression in lesional Hidradenitis Suppurativa skin, whereas the protein concentrations of interleukin-17 were found to be normal compared to healthy control skin in one other study. A phase II clinical trial on anti- interleukin-17 therapy in Hidradenitis Suppurativa is ongoing.
Malcolm C. Veidenheimer - One of the best experts on this subject based on the ideXlab platform.
-
Perianal Hidradenitis Suppurativa
Diseases of the Colon & Rectum, 1990Co-Authors: Othon Wiltz, David J. Schoetz, John J. Murray, Patricia L. Roberts, John A. Coller, Malcolm C. VeidenheimerAbstract:Perianal Hidradenitis Suppurativa, a chronic recurrent inflammatory disease of apocrine glands, adjacent anal canal skin, and soft tissues, is characteristically ignored and misdiagnosed. A retrospective analysis of 43 patients with perianal Hidradenitis Suppurativa was performed; 40 patients (93 percent) were male and 3 (7 percent) were female, with a median age at presentation of 29 years. Symptoms, including pain, swelling, purulent discharge, and pruritus, had been present for a median of six years. Diagnoses at the time of presentation included pilonidal disease (28 percent), anal fistula (37 percent), and perirectal abscess (16 percent). Associated medical conditions included diabetes (12 percent) and obesity (12 percent), and 70 percent of the patients were smokers. Once the correct diagnosis was established, 72 percent of patients had wide local excision with healing by secondary intention, and 28 percent of patients had incision and drainage or limited local excision. Although 67 percent of the patients had recurrence of disease after initial treatment, wide excision was more successful in preventing recurrence. Skin grafting failed uniformly, and colostomy was rarely necessary. Despite its relatively common occurrence, perianal Hidradenitis Suppurativa is infrequently diagnosed correctly and recurs in many patients despite appropriate surgical treatment, making the disease a source of frustration for surgeon and patient alike .
Jason Teitelbaum - One of the best experts on this subject based on the ideXlab platform.
-
painful Hidradenitis Suppurativa
The Clinical Journal of Pain, 2010Co-Authors: Howard S. Smith, Jerome D. Chao, Jason TeitelbaumAbstract:Hidradenitis Suppurativa (HS) is a chronically relapsing skin disorder characterized by recurring inflammatory lesion in hair and apocrine gland-bearing skin creases in the axilla; groin or perineum, buttocks, and/or breast. HS may lead to painful eruptions and malodorous discharge significantly detracting from quality of life. HS causes a high degree of morbidity with the highest scores obtained for the level of pain caused by the disease. The majority of patients rated their pain on a Numerical Rating Scale-11 ranging from 4/10 to 10/10 and described it at various times as hot, burning, pressure, stretching, cutting, sharp, taut, splitting, gnawing, pressing, sore, throbbing, and aching. Despite the severe pain associated with this disease, HS has been essentially ignored in the pain medicine literature. It is hoped that greater understanding of the diagnosis, pathophysiology, and potential treatment options available for patients with HS, may help put pain specialists in a better position to contribute to the overall care of patients with significantly painful HS. This article reviews HS and pain. Potential mechanisms of modulating nociceptive processes in the skin are presented. A greater understanding of the diagnosis, pathophysiology, and potential treatment options for HS patients may help providers to be better able to contribute to care of patients with painful Hidradenitis Suppurativa.
-
Painful Hidradenitis Suppurativa.
The Clinical Journal of Pain, 2010Co-Authors: Howard S. Smith, Jerome D. Chao, Jason TeitelbaumAbstract:Hidradenitis Suppurativa (HS) is a chronically relapsing skin disorder characterized by recurring inflammatory lesion in hair and apocrine gland-bearing skin creases in the axilla; groin or perineum, buttocks, and/or breast. HS may lead to painful eruptions and malodorous discharge significantly det
Hamzavi Iltefat - One of the best experts on this subject based on the ideXlab platform.
-
Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017
Henry Ford Health System Scholarly Commons, 2019Co-Authors: Shavit Eran, Frew, John W., Alavi Afsaneh, Bechara, Falk G, Bennett, Richard G, Bourcier Marc, Cibotti Ricardo, Daveluy Steven, Garg Amit, Hamzavi IltefatAbstract:The 2nd Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) took place on 03-05 November 2017 in Detroit, Michigan, USA. This symposium was a joint meeting of the Hidradenitis Suppurativa Foundation (HSF Inc.) founded in the USA, and the Canadian Hidradenitis Suppurativa Foundation (CHSF). This was the second annual meeting of the SHSA with experts from different disciplines arriving from North America, Europe and Australia, in a joint aim to discuss most recent innovations, practical challenges and potential solutions to issues related in the management and care of Hidradenitis Suppurativa patients. The last session involved clinicians, patients and their families in an effort to educate them more about the disease
-
Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017
'Wiley', 2019Co-Authors: Shavit Eran, Alavi Afsaneh, Bechara, Falk G, Bourcier Marc, Cibotti Ricardo, Daveluy Steven, Garg Amit, Bennett Richard, Frew John, Hamzavi IltefatAbstract:International audienceThe 2nd Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) took place on 03-05 November 2017 in Detroit, Michigan, USA. This symposium was a joint meeting of the Hidradenitis Suppurativa Foundation (HSF Inc.) founded in the USA, and the Canadian Hidradenitis Suppurativa Foundation (CHSF). This was the second annual meeting of the SHSA with experts from different disciplines arriving from North America, Europe and Australia, in a joint aim to discuss most recent in-novations, practical challenges and potential solutions to issues related in the man-agement and care of Hidradenitis Suppurativa patients. The last session involved clinicians, patients and their families in an effort to educate them more about the diseas
Othon Wiltz - One of the best experts on this subject based on the ideXlab platform.
-
Perianal Hidradenitis Suppurativa
Diseases of the Colon & Rectum, 1990Co-Authors: Othon Wiltz, David J. Schoetz, John J. Murray, Patricia L. Roberts, John A. Coller, Malcolm C. VeidenheimerAbstract:Perianal Hidradenitis Suppurativa, a chronic recurrent inflammatory disease of apocrine glands, adjacent anal canal skin, and soft tissues, is characteristically ignored and misdiagnosed. A retrospective analysis of 43 patients with perianal Hidradenitis Suppurativa was performed; 40 patients (93 percent) were male and 3 (7 percent) were female, with a median age at presentation of 29 years. Symptoms, including pain, swelling, purulent discharge, and pruritus, had been present for a median of six years. Diagnoses at the time of presentation included pilonidal disease (28 percent), anal fistula (37 percent), and perirectal abscess (16 percent). Associated medical conditions included diabetes (12 percent) and obesity (12 percent), and 70 percent of the patients were smokers. Once the correct diagnosis was established, 72 percent of patients had wide local excision with healing by secondary intention, and 28 percent of patients had incision and drainage or limited local excision. Although 67 percent of the patients had recurrence of disease after initial treatment, wide excision was more successful in preventing recurrence. Skin grafting failed uniformly, and colostomy was rarely necessary. Despite its relatively common occurrence, perianal Hidradenitis Suppurativa is infrequently diagnosed correctly and recurs in many patients despite appropriate surgical treatment, making the disease a source of frustration for surgeon and patient alike .